Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (351-360 of 448) with videos related to

Pageof 45
Sort By:
RMD Open|November 28, 2024
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosisRucsandra Dobrota, Alexandru Garaiman, Kim Fligelstone, et al.
The Journal of Rheumatology|March 3, 2011
Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in systemic sclerosis: results from 2 large European Caucasian cohortsBaptiste Coustet, Sandeep K Agarwal, Pravitt Gourh, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Rheumatology (Oxford, England)|December 7, 2013
Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysisAndrea D Keck, Chingching Foocharoen, Edoardo Rosato, et al.
Journal of Hypertension|September 1, 2007
Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS studyJoël Constans, Christine Germain, Philippe Gosse, et al.
Thorax|October 5, 2023
Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysisSabina Guler, Adela-Cristina Sarbu, Odile Stalder, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
The Lancet. Rheumatology|January 24, 2024
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohortMuriel Elhai, Nanthara Sritharan, Marouane Boubaya, et al.
Clinical and Experimental Rheumatology|October 3, 2018
Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) databasePatricia E Carreira, Loreto Carmona, Beatriz E Joven, et al.
Pageof 45

Showing results (351-360 of 448) with videos related to

Sort By:
Pageof 45
RMD Open|November 28, 2024
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosisRucsandra Dobrota, Alexandru Garaiman, Kim Fligelstone, et al.
The Journal of Rheumatology|March 3, 2011
Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in systemic sclerosis: results from 2 large European Caucasian cohortsBaptiste Coustet, Sandeep K Agarwal, Pravitt Gourh, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Rheumatology (Oxford, England)|December 7, 2013
Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysisAndrea D Keck, Chingching Foocharoen, Edoardo Rosato, et al.
Journal of Hypertension|September 1, 2007
Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS studyJoël Constans, Christine Germain, Philippe Gosse, et al.
Thorax|October 5, 2023
Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysisSabina Guler, Adela-Cristina Sarbu, Odile Stalder, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
The Lancet. Rheumatology|January 24, 2024
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohortMuriel Elhai, Nanthara Sritharan, Marouane Boubaya, et al.
Clinical and Experimental Rheumatology|October 3, 2018
Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) databasePatricia E Carreira, Loreto Carmona, Beatriz E Joven, et al.
Pageof 45